title: Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Samer A
authors.identifier: 0000-0002-5105-6691
authors.initials: SA
authors.lastname: Srour
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Hun J
authors.initials: HJ
authors.lastname: Lee
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Krystle
authors.initials: K
authors.lastname: Nomie
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Haige
authors.initials: H
authors.lastname: Ye
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Wendy
authors.initials: W
authors.lastname: Chen
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Onyeka
authors.initials: O
authors.lastname: Oriabure
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Jorge
authors.initials: J
authors.lastname: Romaguera
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.|Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Michael L
authors.initials: ML
authors.lastname: Wang
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000069286:Bortezomib / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D000077269:Lenalidomide / Q000008:administration & dosage; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010880:Piperidines; D011720:Pyrazoles / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D000069283:Rituximab / Q000008:administration & dosage
chemical_list: D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000069283:Rituximab; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide; D000225:Adenine
keywords: ibrutinib-resistant; mantle cell lymphoma; relapsed